Bracco nets expanded labeling for MR agent

The FDA has approved the use of Bracco Diagnostics' MultiHance (gadobenate dimeglumine) injection, 529 mg/mL, in MR angiography (MRA) to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease.

MultiHance is a gadolinium-based contrast agent approved for intravenous use in MR imaging of the central nervous system (CNS) in adults and pediatric patients. The recommended dose for both MRI of the CNS and MRA exams is 0.1 mmol/kg (0.2 mL/kg) of MultiHance.

The approval of MultiHance in MRA was granted based on data submitted to the FDA that included safety and efficacy results from two large, prospective, multicenter clinical trials (one for each arterial vascular territory: renal and aorto-ilio-femoral), according to the Princeton, N.J.-based company.



Around the web

No devices need to be returned at this time. However, the FDA warned, using these heart pumps without reviewing the updated instructions could result in "serious injury or death.” 

The FDA recently cleared the company's cable-free, credit card-sized heart monitor that produces 12-lead ECGs.

If 25% tariffs go into effect, it could have a big impact on the cost of medical imaging and radiotherapy systems, with many manufacturing facilities in Mexico.